Dupilumab for AD: conjunctivitis, eosinophilia more common in real-world study

  • Faiz S & al.
  • J Am Acad Dermatol
  • 27 Feb 2019

  • curated by Brian Richardson, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Treatment of atopic dermatitis (AD) with dupilumab (Dupixent) was associated with a higher real-world incidence of conjunctivitis and eosinophilia than that reported in clinical studies.
  • Efficacy was similar to that reported in clinical trials.

Why this matters

  • Real-world studies are essential for validating results from clinical trials, which only represent a select population.

Key results

  • 16.6% of patients achieved ≥75% improvement in Scoring Atopic Dermatitis (SCORAD75), and 48.8% achieved ≥75% improvement in Eczema Area and Severity Index (EASI75).
  • Median SCORAD and EASI scores were lower at 3 months compared with baseline (25 vs 56 [P−9] and 4.1 vs 17.9 [P−9], respectively).
  • 38.2% of patients experienced conjunctivitis during follow-up compared with 8% in a meta-analysis based on trials.
  • 56.5% of patients experienced eosinophilia during follow-up (vs 33.7% at baseline; P−6) compared with
  • Development of conjunctivitis was associated with a medical history of allergic conjunctivitis (P<.003 whereas eosinophilia during follow-up was associated with at baseline>−9), asthma (P<.001 allergic rhinitis and food allergy>
  • 11.2% of patients discontinued because of an adverse event.

Study design

  • Retrospective study of 241 patients from 29 centers with dupilumab-treated AD.
  • Funding: None.

Limitations

  • No control patient group.